Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL612816 Target Snapshot

YOSHIDA · CELL-LINE · Rattus norvegicus

10Compounds
7Assays
2Approved Drugs
4.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats YOSHIDA as ChEMBL target CHEMBL612816. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
YOSHIDA
CELL-LINE · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL612816
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether YOSHIDA still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelYOSHIDA
UniProt AccessionN/A

YOSHIDA

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as YOSHIDA.

Review nameYOSHIDA
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase I
Assay Mix

Activity Type Distribution

IC504.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL178 8.13 IC50 7.4 Approved
CHEMBL428647 8.1 IC50 7.9 Approved
CHEMBL17289 6.85 IC50 140.0 Preclinical
CHEMBL322225 6.18 IC50 660.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
0
5.5
1
6.0
1
6.5
0
7.0
0
7.5
2
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

PACLITAXEL
CHEMBL428647
Approved 1992
DAUNORUBICIN
CHEMBL178
Approved 1979
Assay Landscape

Assay Landscape

7
Total Assays
4
Tested Compounds
1
Assay Types
Functional — 7 assays, 4 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 6 0
cell-based format 1 4 7.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine